cangrelor and Thromboembolism

cangrelor has been researched along with Thromboembolism* in 3 studies

Reviews

1 review(s) available for cangrelor and Thromboembolism

Article	Year
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2021, 10-12, Volume: 78, Issue:15 Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in patients who cannot discontinue dual antiplatelet therapy (DAPT) before surgery is unclear. Current guidelines, based on surgical and clinical characteristics, provide risk stratification for bridging therapy with intravenous antiplatelet agents, but management is guided primarily by expert opinion. This review summarizes perioperative risk factors to consider before discontinuing DAPT and reviews the data for intravenous bridging therapies. Published reports have included bridging options such as small molecule glycoprotein IIb/IIIa inhibitors (eptifibatide or tirofiban) and cangrelor, an intravenous P2Y Topics: Adenosine Monophosphate; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thromboembolism; Tirofiban	2021

Article

Year

Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.

Journal of the American College of Cardiology, 2021, 10-12, Volume: 78, Issue:15

Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in patients who cannot discontinue dual antiplatelet therapy (DAPT) before surgery is unclear. Current guidelines, based on surgical and clinical characteristics, provide risk stratification for bridging therapy with intravenous antiplatelet agents, but management is guided primarily by expert opinion. This review summarizes perioperative risk factors to consider before discontinuing DAPT and reviews the data for intravenous bridging therapies. Published reports have included bridging options such as small molecule glycoprotein IIb/IIIa inhibitors (eptifibatide or tirofiban) and cangrelor, an intravenous P2Y

Topics: Adenosine Monophosphate; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thromboembolism; Tirofiban

2021

Other Studies

2 other study(ies) available for cangrelor and Thromboembolism

Article	Year
Use of a novel antiplatelet agent cangrelor in an infant supported with a ventricular assist device. Artificial organs, 2020, Volume: 44, Issue:5 Topics: Adenosine Monophosphate; Fontan Procedure; Heart-Assist Devices; Humans; Hypoplastic Left Heart Syndrome; Infant; Male; Norwood Procedures; Palliative Care; Platelet Aggregation Inhibitors; Thromboembolism; Treatment Outcome; Ventricular Dysfunction	2020
In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arteriosclerosis, thrombosis, and vascular biology, 2003, Mar-01, Volume: 23, Issue:3 ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs.. Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 microg x kg x min(-1) IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P<0.05) reduced the total duration of embolization (by 52% and 36%, respectively), and fewer and smaller emboli were produced. The size of the initial thrombus was significantly reduced (P<0.005), but its stability was unaffected: plug formation was still effective.. These findings demonstrate that ADP and its P2Y12 receptor are involved in thrombus growth and especially in the formation of emboli on the downstream side of the initial thrombus. This may explain the beneficial effects of P2Y12 receptor antagonists in secondary prevention of ischemic events in patients with arterial thrombosis. Topics: Adenosine Monophosphate; Administration, Oral; Animals; Blood Platelets; Calcium; Clopidogrel; Female; Male; Membrane Proteins; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine	2003

Article

Year

Use of a novel antiplatelet agent cangrelor in an infant supported with a ventricular assist device.

Artificial organs, 2020, Volume: 44, Issue:5

Topics: Adenosine Monophosphate; Fontan Procedure; Heart-Assist Devices; Humans; Hypoplastic Left Heart Syndrome; Infant; Male; Norwood Procedures; Palliative Care; Platelet Aggregation Inhibitors; Thromboembolism; Treatment Outcome; Ventricular Dysfunction

2020

In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.

Arteriosclerosis, thrombosis, and vascular biology, 2003, Mar-01, Volume: 23, Issue:3

ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs.. Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 microg x kg x min(-1) IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P<0.05) reduced the total duration of embolization (by 52% and 36%, respectively), and fewer and smaller emboli were produced. The size of the initial thrombus was significantly reduced (P<0.005), but its stability was unaffected: plug formation was still effective.. These findings demonstrate that ADP and its P2Y12 receptor are involved in thrombus growth and especially in the formation of emboli on the downstream side of the initial thrombus. This may explain the beneficial effects of P2Y12 receptor antagonists in secondary prevention of ischemic events in patients with arterial thrombosis.

Topics: Adenosine Monophosphate; Administration, Oral; Animals; Blood Platelets; Calcium; Clopidogrel; Female; Male; Membrane Proteins; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine

2003